BEBabette Fiebke van Esch

Babette Fiebke van Esch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Babette Fiebke van Esch has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Menière’s disease clinical subtypes and baseline characteristics in a Dutch patient cohort

    by Maud M.E. Boreel, Hester S. Verhoeven, Babette F. van Esch, Tjard R Schermer, Peter Paul G. van Benthem, Tjasse D. Bruintjes

    Purpose: The aim of this study is to provide a detailed description of a Dutch cohort of patients with Menière’s disease (MD), classify patients into clinical subtypes according to the criteria proposed by Frejo et al., and compare the distribution of these subtypes with cohorts from Spain, the United States, and China. Methods: A retrospective, cross-sectional chart review was conducted among 375 patients diagnosed with definite MD at two Dutch medical centers. Patients were classified into five clinical subtypes of unilateral MD or 5 subtypes of bilateral MD. Baseline characteristics were analyzed and compared across subtypes and international cohorts. Results: Of the 375 included patients, 335 had unilateral MD of which 49.0% were type 1 (classic MD), 23.6% type 2 (delayed MD), 6.6% type 3 (familial MD), 13.7% type 4 (migraine-associated MD), and 7.2% type 5 (autoimmune MD). This distribution differed significantly from the Spanish cohort regarding the delayed and familial subgroups, and from the Chinese cohort regarding the familial subgroup. Forty cases of bilateral MD were observed, with differences in the synchronic subgroup when compared to the Spanish cohort. Conclusion: This study describes the clinical subtypes of MD within a Dutch patient cohort, with subtype distributions more closely resembling those of the American and Chinese cohorts than the Spanish cohort. This suggest regional variation in the clinical expression of MD.


  • Open Access

    Vestibular Function and Complaints in Patients With Untreated Unilateral Vestibular Schwannoma

    by Constanza Fuentealba Bassaletti, Babette F. van Esch, Kenny van Lieshout, Heiko Locher, Jeroen C. Jansen, Radboud W. Koot, Tjasse D. Bruintjes, Peter Paul G. van Benthem, Erik F. Hensen

    Objectives: The primary aim of this study is to assess the vestibular function of patients with an untreated unilateral vestibular schwannoma (VS) using multiple objective tests, and to correlate outcomes with vestibular complaints and QoL. The secondary aim is to evaluate patient and tumor characteristics that may affect objective and subjective vestibular function. Methods: In this prospective cross-sectional study, patients with untreated unilateral VS aged 18 years or older were included and evaluated using the caloric test, vHIT, cVEMP, DHI, PANQOL, and SF-36. Tumor and patient characteristics were retrieved from the patient files. Linear regression analyses were performed to identify predictors for vestibular function. Results: The majority (89%) showed one or more objective vestibular abnormalities. The lateral and anterior vHIT correlated with the caloric test results, hearing loss [ie, a lower gain is associated with a higher hearing threshold and thus more severe hearing impairment ( r =−0.57, P r =−0.41, P =0.003)]. However, no significant correlations between objective vestibular test results and vestibular complaints or quality of life were found. Tumor characteristics did not correlate with subjective outcomes (dizziness, quality of life). Even so, DHI scores showed a strong correlation with PANQOL scores (χ 2 =28.6, P <0.001). Conclusion: Vestibular complaints significantly impact the quality of life in vestibular schwannoma patients. Whereas vHIT does correlate with tumor size and hearing loss, neither objective vestibular function tests nor tumor characteristics correlate significantly with vestibular complaints or quality of life in this patient group.


  • Open Access

    The effectiveness of intratympanic injections with methylPREDnisolon versus placebo in the treatment of vertigo attacks in MENière’s disease (PREDMEN trial): a study protocol for a phase-3 multicentre, double-blinded, randomised, placebo-controlled trial

    by Maud Martina Emilie Boreel, Babette van Esch, Tjard R Schermer, Berber M Mol, Peter Paul van Benthem, Tjasse D Bruintjes

    Introduction Intratympanic corticosteroids are commonly used in the treatment of Menière’s disease (MD). However, few and small randomised controlled trials (RCT) on the effectiveness of intratympanic corticosteroids have been performed. A recent Cochrane review suggested that a well-conducted placebo-controlled RCT with a large study population is required to evaluate the effectiveness of the use of intratympanic corticosteroids in MD. The following protocol describes a phase-3 multicentre, double-blinded, randomised, placebo-controlled trial to compare the effectiveness of methylprednisolone (62.5 mg/mL) to a placebo (sodium chloride 0.9%). Methods and analysis We aim to recruit 148 patients with unilateral MD from six hospitals in the Netherlands. Patients will be randomly assigned to either the methylprednisolone or the placebo group. Two injections will be given, one at baseline and one after 2 weeks. Follow-up assessments will be done at 3, 6, 9 and 12 months. The primary outcome will be the frequency of vertigo attacks. Attacks will be evaluated daily with the DizzyQuest app. Secondary outcomes include hearing loss, tinnitus, health-related quality of life, use of co-interventions and escape medication, (serious) adverse events and cost-effectiveness. These will be evaluated with audiometry and multiple commonly used, validated questionnaires. For the primary and secondary outcomes mixed model analysis, generalised estimating equation analysis and logistic regression analysis will be used. Ethics and dissemination This study was submitted via the Clinical Trials Information System, reviewed and approved by the Medical Research Ethics Committee Leiden The Hague Delft and the local institutional review board of each participating centre. All data will be presented ensuring the integrity and anonymity of patients. Results will be published in scientific journals and presented on (inter)national conferences. Trial registration number This study is registered at ClinicalTrials.gov Protocol Registration and Results System, with the registration ID: NCT05851508.


  • The Diagnostic Value of Multifrequency Tympanometry in Patients with Ménière’s Disease: A Prospective Analysis

    by Marrigje A. de Jong, Babette F. van Esch, Peter Paul G. van Benthem, Hester J. van der Zaag-Loonen, Tjasse D. Bruintjes, Hans G.X.M. Thomeer

    Introduction: Diagnosing Ménière’s disease (MD) by its characteristics such as episodes of vertigo, fluctuating hearing loss, and tinnitus with aural fullness remains challenging. Available tests evaluating the presence of endolymphatic hydrops (EH) are often expensive or time assuming. An in-office quick and simple non-invasive diagnostic test is multifrequency tympanometry (MFT). It can measure conductance at 2 kHz probe tones, which was demonstrated to reflect variations in cochlear pressure. Previous studies investigating MFT as a diagnostic test for MD showed conflicting outcomes possibly biased by their retrospective design. Methods: We prospectively collected MFT results (Y width) in patients with dizziness and compared MFT test results in affected (group 1) and unaffected (group 2) ears of 37 MD subjects and in control ears of 33 non-MD subjects (group 3). Results: The mean value of the Y width in affected ears was 315.6 ± 70.2 daPa compared to 292.3 ± 98.6 daPa in unaffected ears in MD subjects and 259.4. ± 60.6 daPa in the non-MD group. A positive test result (i.e., a Y width of 235 daPa or more) was found in 35 ears in the MD group, 21 times involving the affected ear and 14 times involving the unaffected ear, compared to 16 in the non-MD group. No significant differences between the three groups could be demonstrated (p > 0.05). We found a sensitivity of 58.3% and specificity of 66.3% for detecting EH in an affected ear in MD subjects. Conclusion: There is a trend towards increased conductance tympanometry in affected ears. However, we noticed a high false positive rate of MFT and do not support standardized use of MFT as an additional diagnostic tool for detecting EH in MD patients. A negative test result on the contrary is unlikely related to EH.


  • Interventions for Menière’s disease: an umbrella systematic review

    by Babette Fiebke van Esch, Hester van der Zaag-Loonen, Tjasse Bruintjes, Ton Kuijpers, Peter Paul G van Benthem

    Objectives To systematically review the efficacy of interventions for Menière’s disease (MD) to report clinical implications of the results and to identify areas for future valuable research. Methods In line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Abstracts (PRISMA-A) guideline, a systematic online database search was conducted in which MEDLINE (PubMed), Embase (Ovid) and CENTRAL (Cochrane Library) were searched until May 2021 in order to search for the efficacy of treatment was analysed in a systematic review. Systematic reviews (SRs) on treatments for MD were screened for eligible interventions. From these SRs, we included placebo randomised controlled trials (RCTs). A separate search was conducted to identify RCTs on treatment modalities that were systematically reviewed yet published after the conduction of these SRs. The primary outcome was control of vertigo as defined by the American guideline as published in 1995. The PRISMA-A and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to appraise and evaluate the certainty of evidence. Results We found five SRs from which 19 RCTs were extracted. Five RCTs were added by the separate search resulting in a total of 25 RCTs (n=1248) which evaluated the efficacy of betahistine dihydrochloride, intratympanic injections with gentamicin or steroids, endolymphatic sac surgery and pressure pulse therapy. Evidence on the efficacy of interventions for patients with MD is generally of low certainty. Betahistine (48 mg per day and 144 mg per day) and positive pressure therapy probably do not reduce MD symptoms when compared with placebo. Intratympanic injection with gentamicin or steroids, or treatment with endolymphatic surgery may reduce symptoms in MD when compared with placebo. Conclusions A definite effective and well-tolerated therapy for MD has yet to be discovered and information on the natural course of disease is one of the biggest flaws in current research. PROSPERO registration number CRD4201502424.


  • Open Access

    Betahistine in Ménière’s Disease or Syndrome: A Systematic Review

    by Babette Van Esch, Hester van der Zaag-Loonen, Tjasse Bruintjes, Peter Paul van Benthem

    Background: Ménière’s disease is characterized by recurrent episodes of vertigo, hearing loss, and tinnitus, often with a feeling of fullness in the ear. Although betahistine is thought to be specifically effective for Ménière’s disease, no evidence for a benefit from the use of betahistine exists, despite its widespread use. Reassessment of the effect of betahistine for Ménière’s disease is now warranted. Search Methods: We searched for randomized controlled trials (RCTs) in the Central Register of Controlled Trials (CENTRAL), Ovid Medline, Ovid Embase, CINAHL, Web of Science, Clinicaltrials.gov, ICTRP, and additional sources for published and unpublished trials, in which betahistine was compared to placebo. Data Collection and Analysis: Our outcomes involved vertigo, significant adverse effect (upper gastrointestinal discomfort), hearing loss, tinnitus, aural fullness, other adverse effects, and disease-specific health-related quality of life. We used GRADE to assess the quality of the evidence. Main Results: We included 10 studies: 5 studies used a crossover design and the remaining 5 were parallel-group RCTs. One study with a low risk of bias found no significant difference between the betahistine groups and placebo with respect to vertigo after a long-term follow-up period. No significant difference in the incidence of upper gastrointestinal discomfort was found in 2 studies (low-certainty evidence). No differences in hearing loss, tinnitus, or well-being and disease-specific health-related quality of life were found (low- to very low-certainty of evidence). Data on aural fullness could not be extracted. No significant difference between the betahistine and the placebo groups (low-certainty evidence) could be demonstrated in the other adverse effect outcome with respect to dull headache. The pooled risk ratio for other adverse effect in the long term demonstrated a lower risk in favor of placebo over betahistine. Conclusions: High-quality studies evaluating the effect of betahistine on patients with Ménière’s disease are lacking. However, one study with low risk of bias found no evidence of a difference in the effect of betahistine on the primary outcome, vertigo, in patients with Ménière’s disease when compared to placebo. The main focus of future research should be on the use of comparable outcome measures by means of patient-reported outcome measures.


  • Open Access

    Saccades Matter: Reduced Need for Caloric Testing of Cochlear Implant Candidates by Joint Analysis of v-HIT Gain and Corrective Saccades

    by Constanza Fuentealba Bassaletti, Babette F. van Esch, Jeroen J. Briaire, Peter Paul G. van Benthem, Erik F. Hensen, Johan H. M. Frijns

    Objectives: Video head impulse test (v-HIT) is a quick, non-invasive and relatively cheap test to evaluate vestibular function compared to the caloric test. The latter is, however, needed to decide on the optimal side to perform cochlear implantation to avoid the risk on inducing a bilateral vestibular areflexia. This study evaluates the effectiveness of using the v-HIT to select cochlear implant (CI) candidates who require subsequent caloric testing before implantation, in that way reducing costs and patient burden at the same time.Study Design: Retrospective study using clinical data from 83 adult CI-candidates, between 2015 and 2020 at the Leiden University Medical Center.Materials and Methods: We used the v-HIT mean gain, MinGain_LR, the gain asymmetry (GA) and a newly defined parameter, MGS (Minimal Gain & Saccades) as different models to detect the group of patients that would need the caloric test to decide on the ear of implantation. The continuous model MGS was defined as the MinGain_LR, except for the cases with normal gain (both sides ≥0.8) where no corrective saccades were present. In the latter case MGS was defined to be 1.0 (the ideal gain value).Results: The receiver operating characteristics curve showed a very good diagnostic accuracy with and area under the curve (AUC) of 0.81 for the model MGS. The v-HIT mean gain, the minimal gain and GA had a lower diagnostic capacity with an AUC of 0.70, 0.72, and 0.73, respectively. Using MGS, caloric testing could be avoided in 38 cases (a reduction of 46%), with a test sensitivity of 0.9 (i.e., missing 3 of 28 cases).Conclusions: The newly developed model MGS balances the sensitivity and specificity of the v-HIT better than the more commonly evaluated parameters such as mean gain, MinGain_LR and GA. Therefore, taking the presence of corrective saccades into account in the evaluation of the v-HIT gain can considerably reduce the proportion of CI-candidates requiring additional caloric testing.


  • Betahistine for Ménière's disease or syndrome

    by Babette Van Esch, Hester J Van Der Zaag-Loonen, Tjasse Bruintjes, Louisa Murdin, Adrian James, Peter Paul Van Benthem


  • Open Access

    Video-head impulse test results in patients with Menière’s disease related to duration and stage of disease

    by B F Van Esch, K Abolhosseini, S Masius-Olthof, H J Van Der Zaag-Loonen, P P G Van Benthem, Tj D Bruintjes

    BACKGROUND: The video-head impulse test employs the vestibulo-ocular reflex (VOR) to assess vestibular function. To this day, no consensus has been reached among scientists in terms of whether or not vHIT results change in MD patients as the disease


  • Comparing the critical features of e-applications for three-dimensional anatomy education

    by Marijn Zilverschoon, Evelien M.G. Kotte, Babette van Esch, Olle Ten Cate, Eugene J. Custers, Ronald L.A.W. Bleys